Barmherzige Brueder gemeinnuetzige Krankenhaus GmbH

The Clinic for Oncology and Hematology at Barmherzige Brueder gemeinnuetzige Krankenhaus GmbH in Regensburg is active in hematologic cancer research, with studies focused on diseases such as acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, and several forms of lymphoma. These trials are mainly designed to improve treatment effectiveness, deepen remission, and refine long-term disease control.

• Research in acute leukemia includes new treatment combinations for acute myeloid leukemia and acute lymphoblastic leukemia.
• Studies in chronic leukemias and lymphoid cancers examine better ways to manage CLL, SLL, mantle cell lymphoma, and follicular lymphoma.
• Myeloma trials evaluate approaches intended to strengthen response depth and sustain disease control in multiple myeloma.

Overall, this site contributes to advancing blood cancer care by testing therapies that may improve survival, response quality, and treatment tolerability.

Another major focus at the Regensburg site is solid tumor research, especially cancers of the stomach, gastroesophageal junction, colon, rectum, esophagus, lung, and ovary. The studies aim to test new treatment strategies, improve survival, and support better outcomes before and after surgery.

• Gastroesophageal and gastric cancers are being studied through trials of combined systemic and perioperative treatment approaches.
• Colorectal and rectal cancer studies explore ways to improve disease-free survival and preserve organ function.
• Lung cancer, pleural mesothelioma, and other advanced solid tumors are included in trials evaluating newer immunotherapy-based strategies.

These studies reflect a broad effort to improve both curative and advanced cancer care through more effective and personalized treatment options.

The site also conducts research in digestive system diseases, with a strong emphasis on cancers and inflammatory conditions affecting the colon, rectum, stomach, and esophagus, as well as ulcerative colitis. The main purpose is to evaluate better therapies, improve recovery after treatment, and support more precise care decisions.

• Colorectal cancer trials examine preoperative, postoperative, and organ-preserving treatment strategies.
• Upper gastrointestinal cancer studies assess approaches for gastric and esophagogastric adenocarcinoma.
• Inflammatory bowel disease research includes work in ulcerative colitis to improve symptom control and remission.

These efforts show a clear interest in both cancer care and chronic digestive disease management.

Within respiratory tract disease research, the site is involved in studies of non-small cell lung cancer, pleural mesothelioma, and interstitial lung disease linked to autoimmune conditions. The trials are designed to test improved treatments, measure disease control, and better understand outcomes in difficult-to-treat lung-related illnesses.

• Stage III unresectable NSCLC studies evaluate new combinations intended to delay progression.
• Pleural mesothelioma trials focus on extending survival and improving response in advanced disease.
• Interstitial lung disease research looks at reducing lung involvement and improving respiratory health.

This area highlights the center’s involvement in both thoracic oncology and non-malignant lung disease research.

In addition to cancer-focused work, the Barmherzige Brueder gemeinnuetzige Krankenhaus GmbH participates in research on congenital and neonatal conditions, including fetal heart development disorders. These studies aim to improve early diagnosis and support better outcomes for unborn babies with structural abnormalities.

• Fetal cardiac development research addresses underdeveloped structures on the left side of the heart.
• Trial objectives center on improving prenatal care and evaluating whether treatment during pregnancy can support growth and development.
• This work adds a maternal-fetal medicine dimension to the site’s broader clinical research portfolio.

Although smaller in scope, this area shows the site’s interest in conditions that begin before birth and may benefit from earlier intervention.